Table 1.

Basic electrode and membrane properties from whole-cell recordings

Treatment group	Electrode (MΩ)	Access resistance (MΩ)	Capacitance (pF)	Holding current (pA)	n
Control	2.42 ± 0.06	10.01 ± 0.54	60.84 ± 4.79	147.91 ± 11.92	18
Rapamycin, 1 h	2.45 ± 0.10	9.73 ± 0.57	51.37 ± 3.62	113.80 ± 12.18	4
Rapamycin, 24 h	2.45 ± 0.08	10.44 ± 0.66	60.15 ± 3.69	133.26 ± 7.50	20
Rapamycin, 4 d	2.61 ± 0.07	10.04 ± 0.77	54.47 ± 2.86	113.74 ± 11.09	20
Nimodipine	2.55 ± 0.08	9.13 ± 0.33	53.07 ± 1.02	103.93 ± 17.42	12
Rapamycin (4 d) + Nimodipine	2.47 ± 0.08	8.97 ± 0.44	53.69 ± 1.75	107.77 ± 19.18	10
siRNA FKBP	2.62 ± 0.06	9.03 ± 0.45	57.47 ± 2.63	131.63 ± 12.02	23
siRNA nontargeted	2.52 ± 0.04	9.25 ± 0.060	57.86 ± 3.16	134.66 ± 16.58	19
siRNA vehicle	2.43 ± 0.05	9.05 ± 0.053	57.88 ± 2.90	128.20 ± 21.63	23

No differences in basic properties were observed across conditions; means ± SEM.